Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Supports restricting routine use to troponins and BNP; leaves open rigorous validation before adopting emerging biomarkers.
Cardiac markers or, more correctly, cardiac biomarkers are now integral to diagnostic and management strategies in cardiovascular disease. Scarcely a week passes without another publication claiming a new and allegedly useful cardiac biomarker. The actuality is that only two cardiac biomarkers are currently in routine clinical use; the measurement of the cardiac troponins for the differential diagnosis of suspected acute coronary syndromes and measurement of B type natriuretic peptide (BNP) for the differential diagnosis of suspected cardiac failure.
No takes yet. Share an insight, caveat, or question.
Paul Collinson (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: